ACE and kidney disorder: Stronger evidence of the renoprotective effect of ACE inhibitors were provided by the Ramipril Efficacy in Nephropathy (REIN) study, showing that with comparable BP control, treatment with the ACE inhibitor ramipril reduced the rate of GFR decline and progression to ESRF in patients with non-diabetic proteinuric nephropathies compared with placebo.